| Name | Title | Contact Details |
|---|
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.
Aristea Therapeutics (Air-iss-tay-uh) is a clinical-stage drug development company developing novel therapies to treat serious inflammatory diseases.
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
R-Research is a Trenton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Santen Inc. is a Napa, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.